Datapoint: Arcutis Scores New Indication for Zoryve
The FDA approved a new drug concentration and a new indication to Arcutis Biotherapeutics, Inc.’s Zoryve (roflumilast) 0.15% cream for the treatment of mild to moderate atopic dermatitis in people at least 6 years old. The agency initially approved the first topical PDE4 inhibitor on July 29, 2022. It remains available as a 0.3% cream and a foam. The topical was first approved in 2011 for the treatment of psoriasis, an indication for which it currently holds covered or better status for 70% of all insured lives under the pharmacy benefit.
SOURCE: MMIT Analytics, as of 7/17/24
© 2025 MMIT